Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.
MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback